West Pharmaceutical Services (NYSE:WST) Releases Quarterly Earnings Results, Beats Expectations By $0.29 EPS

West Pharmaceutical Services (NYSE:WST) released its quarterly earnings results on Thursday. The medical instruments supplier reported $2.37 EPS for the quarter, beating the consensus estimate of $2.08 by $0.29, Zacks reports. The business had revenue of $872.30 million for the quarter, compared to analysts’ expectations of $839.98 million. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. West Pharmaceutical Services’s revenue was up 13.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.84 earnings per share. West Pharmaceutical Services updated its Q3 2026 guidance to 2.140-2.240 EPS and its FY 2026 guidance to 8.850-9.050 EPS.

Here are the key takeaways from West Pharmaceutical Services’ conference call:

• West delivered Q2 2026 results above expectations, with revenue of $872 million up 13% organically and adjusted EPS of $2.37 up 29% year over year.
• The company raised full-year guidance to 10%-11% organic revenue growth and adjusted EPS of $8.85-$9.05, citing strong momentum in the business.
• High-value product components were the main growth engine, with organic growth of 18% led by biologics, Annex 1-related upgrades, and GLP-1 demand. Management said non-GLP-1 HVP components outperformed expectations and still have a multi-year runway.
• The cyber incident still affected West Vantage, holding Q2 growth to 1% and shifting some revenue into the second half. Management said the impact should be made up later this year, with Q3 expected to be the trough for the segment.
• Gross margin and operating margin both improved meaningfully in the quarter, helped by stronger sales mix, pricing, and leverage from higher revenue. West also continued share repurchases, buying back $157 million of stock in Q2.

West Pharmaceutical Services Stock Performance

WST stock opened at $328.61 on Friday. West Pharmaceutical Services has a twelve month low of $223.83 and a twelve month high of $386.00. The company has a quick ratio of 2.04, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. The company has a market cap of $23.22 billion, a P/E ratio of 42.08, a price-to-earnings-growth ratio of 2.77 and a beta of 1.16. The business’s fifty day moving average is $337.02 and its 200-day moving average is $287.43.

West Pharmaceutical Services Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th will be paid a $0.22 dividend. The ex-dividend date of this dividend is Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. West Pharmaceutical Services’s dividend payout ratio is 11.27%.

West Pharmaceutical Services News Roundup

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: West posted a strong second quarter, with adjusted EPS of $2.37 and revenue of $872.3 million, both above expectations. The company also raised full-year 2026 EPS guidance and gave third-quarter guidance that topped consensus, which supports the longer-term outlook. West Reports Second-Quarter 2026 Results
• Positive Sentiment: Demand remains strong for high-value injectable drug components, including products tied to GLP-1 and biologics markets, which helped drive the beat and the higher outlook. Reuters article on raised forecast
• Neutral Sentiment: Investors may be taking profits after the stock’s sharp earnings-driven surge in the prior session, especially since there was no major new negative company announcement or filing behind today’s weakness. Quiver Quantitative article
• Neutral Sentiment: Recent insider sales from two executives may add a small overhang, but the activity is limited and does not appear to be the main driver of the stock’s move. Insider trading details

Insiders Place Their Bets

In other West Pharmaceutical Services news, CAO Chad Winters sold 896 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $300.67, for a total transaction of $269,400.32. Following the transaction, the chief accounting officer owned 1,523 shares in the company, valued at approximately $457,920.41. This trade represents a 37.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Annette F. Favorite sold 2,817 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $305.20, for a total value of $859,748.40. Following the transaction, the vice president owned 16,828 shares of the company’s stock, valued at $5,135,905.60. The trade was a 14.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Aptus Capital Advisors LLC increased its stake in West Pharmaceutical Services by 5.5% in the fourth quarter. Aptus Capital Advisors LLC now owns 905 shares of the medical instruments supplier’s stock valued at $249,000 after purchasing an additional 47 shares in the last quarter. IFM Investors Pty Ltd boosted its position in shares of West Pharmaceutical Services by 0.4% during the fourth quarter. IFM Investors Pty Ltd now owns 13,730 shares of the medical instruments supplier’s stock worth $3,778,000 after purchasing an additional 49 shares in the last quarter. Benjamin Edwards Inc. grew its holdings in shares of West Pharmaceutical Services by 1.7% in the 2nd quarter. Benjamin Edwards Inc. now owns 3,021 shares of the medical instruments supplier’s stock valued at $661,000 after buying an additional 50 shares during the period. Smartleaf Asset Management LLC grew its holdings in shares of West Pharmaceutical Services by 4.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,207 shares of the medical instruments supplier’s stock valued at $334,000 after buying an additional 53 shares during the period. Finally, Caerus Investment Advisors LLC increased its position in shares of West Pharmaceutical Services by 6.2% in the 4th quarter. Caerus Investment Advisors LLC now owns 1,035 shares of the medical instruments supplier’s stock valued at $285,000 after buying an additional 60 shares in the last quarter. Institutional investors own 93.90% of the company’s stock.

Wall Street Analyst Weigh In

WST has been the topic of several research reports. Stephens reaffirmed an “overweight” rating and set a $360.00 price objective on shares of West Pharmaceutical Services in a report on Tuesday, June 2nd. Evercore restated an “outperform” rating and set a $410.00 target price on shares of West Pharmaceutical Services in a research report on Monday, July 6th. BNP Paribas Exane began coverage on West Pharmaceutical Services in a research note on Monday, July 13th. They set an “outperform” rating and a $447.00 price target on the stock. Citigroup reiterated a “buy” rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. Finally, Zacks Research raised West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, West Pharmaceutical Services has a consensus rating of “Buy” and an average target price of $363.17.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.